Register
Forgot your password?

Significance of lipoprotein (A) in the pathogenesisof cardiovascular diseases

Authors: Yaroustovsky M.B., Abramyan M.V.

Company: Bakoulev National Medical Research Center for Cardiovascular Surgery of Ministry of Health of the Russian Federation, Rublevskoe shosse, 135, Moscow, 121552, Russian Federation

For correspondence:  Sign in or register.

Type:  Reviews


DOI: https://doi.org/10.24022/1997-3187-2019-13-1-40-51

For citation: Yaroustovsky M.B., Abramyan M.V. Significance of lipoprotein (a) in the pathogenesis of cardiovascular diseases. Creative Cardiology. 2019; 13 (1): 40–51 (in Russ.). DOI: 10.24022/1997-3187-2019-13-1-40-51

Received / Accepted:  10.01.2019/15.01.2019

Keywords: atherosclerosis lipoprotein (a) lipid disorders dyslipidemia cardiovascular diseases

Download
Full text:  

 

Abstract

The progress of medical technology allows you to look at the problem of the treatment of atherosclerosis and its complications more widely. The development of atherosclerosis depends on many factors, leading among which are dyslipidemia. In clinical practice, there are patients with atherosclerotic lesions of various vessels with normal or slightly elevated lipid levels, which is the reason for skepticism of some doctors about lipid theory. It is clear, that absolutization of the role of lipoproteins, as the best indicators of the risk of ischemic lesions, can lead to an erroneous understanding of the pathogenesis. This suggests the presence of other etiological factors of atherosclerosis. Among the lipid factors, not only high levels of low density lipoproteins (LDL), but also lipoprotein (a) (Lp(a)) have made a certain contribution to the development of atherosclerosis. Today, Lp(a) is even considered an independent risk factor for thrombogenesis and atherogenesis, and a predictor of cardiovascular and microvascular diseases. The structural and functional identity of Lp(a) with LDL and plasminogen determine its role in the pathogenesis of atherothrombosis. The results of many studies indicate the adverse effects of hyperlipoproteidemia on the cardiovascular system. The definition of Lp(a) is important and useful for the early prevention of complications and, if necessary, the choice of treatment.

References

  1. Sokolov A.A., Aleksandrova O.Yu., Kashtalap V.V.,Barbarash O.L., Ezhov M.V. Guidelines on the me-dical care organization to the patients with heredi-tary atherogenic lipid disorders in the regions ofRussia (joint project of the National society for theresearch on atherosclerosis and non-profit partner-ship “The National council of experts on rare dise-ases”). The Bulletin of Contemporary Clinical Medi-cine.2017; 10 (1): 83–8 (in Russ.). DOI: 10.20969/VSKM.2017.10(1).83-88
  2. Safarova M.S., Ezhov M.V. The evolution of viewson lipoprotein(a): from biomarker to the therapeu-tic target. Kardiologiia. 2015; 55 (4): 71–82 (in Russ.).
  3. Li S., Wu N.Q., Zhu C.G., Zhang Y., Guo Y.L., Gao Y. et al. Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease. Atherosclerosis. 2017; 260: 67–74. DOI: 10.1016/j.atherosclerosis.2017.03.021
  4. Nordestgaard B.G., Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J. Lipid. Res. 2016; 57 (11): 1953–75. DOI: 10.1194/jlr.r071233
  5. Pokrovsky S.N., Afanasieva O.I., Safarova M.S., Balakhonova T.V., Matchin Y.G., Adamova I.Y. et al. Specific Lp(a) apheresis: A tool to prove lipoprotein (a) atherogenicity. Atherosclerosis. Suppl. 2017; 30: 166–73. DOI: 10.1016/j.atherosclerosissup.2017.05.004
  6. Verbeek R., Sandhu M.S., Hovingh G.K., Sjouke B., Wareham N.J., ZwindermanA. H. et al. Lipoprotein( a) improves cardiovascular risk prediction based on established risk algorithms. J. Am. Coll. Cardiol. 2017; 69 (11): 1513–5. DOI: 10.1016/j.jacc.2017.01.017
  7. Zueva I.B., Baratashvili G.G., Krivonosov D.S.,Buch A.V., Sidorkevich S.V. The role of lipopro-tein (a) in the development of cardiovascular eventsand the therapeutic potential. Arterial'naya Giper-tenziya (Arterial Hypertension).2016; 22 (3): 232–43(in Russ.). DOI: 10.18705/1607-419X-2016-22-3-232-243
  8. Schmidt K., Noureen A., Kronenberg F., Utermann G. Structure, function, and genetics of lipoprotein (a). J. Lipid. Res. 2016; 57 (8): 1339–59. DOI: 10.1194/jlr.R067314
  9. Pizov N.A., Pizova N.V. Role of lipoprotein (a) inthe development of ischemic stroke and other car-diovascular diseases. Nevrologiya, Neiropsikhiatriya,Psikhosomatika (Neurology, Neuropsychiatry, Psy-chosomatics).2016; 8 (1): 90–5. DOI: 10.14412/2074-2711-2016-1-90-5
  10. Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J. Am. Coll. Cardiol. 2017; 69 (6): 692–711. DOI: 10.1016/j.jacc.2016.11.042
  11. Berg K. A new serum type system in man – the Lp system. Acta. Pathol. Microbiol. Scand. 1963; 59: 369–82.
  12. Cremer P., Nagel D., Labrot B., Mann H., Muche R., Elster H. et al. Lipoprotein Lp(a) as a predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the Prospective Gottingen Risk Incidence and Prevalance Study (GRIPS). Eur. J. Clin. Invest. 1994; 24 (7): 444–53. DOI: 10.1111/j.1365-2362.1994.tb02373.x
  13. Julius U. History of lipidology and lipoprotein apheresis. Atheroscler. Suppl. 2017; 30: 1–8. DOI: 10.1016/j.atherosclerosissup.2017.05.034
  14. Kostner K.M., Marz W., Kostner G.M. When should we measure lipoprotein (a)? Eur. Heart. J. 2013; 34: 3268–76. DOI: 10.1093/eurheartj/eht053
  15. Marcovina S.M., Koschinsky M.L., Albers J.J., Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin. Chem. 2003; 49 (11): 1785–96. DOI: 10.1373/clinchem.2003.023689
  16. Lamon-Fava S., Diffenderfer M.R., Marcovina S.M. Lipoprotein(a) metabolism. Curr. Opin. Lipidol. 2014; 25: 189–93. DOI: 10.1097/mol.0000000000000070
  17. Velkov V.V. Lipoprotein (а): new perspectives forlaboratory diagnosis. Clinical and laboratory consul-tation. 2012; 4 (44): 37–48 (in Russ.).
  18. Kronenberg F., Utermann G. Lipoprotein(a): resurrected by genetics. J. Intern. Med. 2013; 273: 6–30. DOI: 10.1111/j.1365-2796.2012.02592.x
  19. Yeang C., Gordts P.L., Tsimikas S. Novel lipoprotein (a) catabolism pathway via apolipoprotein(a) recycling: adding the plasminogen receptor PlgR (KT) to the list. Circ. Res. 2017; 120 (7): 1050–2. DOI: 10.1161/CIRCRESAHA.117.310700
  20. Erqou S., Thompson A., Di Angelantonio E., Saleheen D., Kaptoge S., Marcovina S., Danesh J. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J. Am. Coll. Cardiol. 2010; 55: 2160–7. DOI: 10.1016/j.jacc.2009.10.080
  21. Rubin J., Kim H.J., Pearson T.A., Holleran S., Berglund L., Ramakrishnan R. The apolipoprotein(a) gene: linkage disequilibria at three loci differs in African Americans and Caucasians. Atheroscler. 2008; 201: 138–47. DOI: 10.1016/ j.atherosclerosis.2008.01.002
  22. Virani S.S., Brautbar A., Davis B.C., Nambi V., Hoogeveen R.C., Sharrett A.R. et al. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012; 125: 241–9. DOI: 10.1161/circulationaha.111.045120
  23. Enas E.A., Senthilkumar A., Chacko V., Puthumana N. Dyslipidemia among Indo-Asians: strategies for identification and management. Brit. J. Diabetes. Vasc. Dis. 2005; 5: 81–90. DOI: 10.1177/14746514050050020601
  24. Anand S.S., Yusuf S., Vuksan V., Devanesen S., Teo K.K., Montague P.A. et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet. 2000; 356 (9226): 279–84. DOI: 10.1016/s0140-6736 (00)02502-2
  25. Ezhov M.V., Safarova M.S., Afanasieva O.I., Pogorelova O.A., Tripoten M.I., Adamova I.Y. et al. Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein (a) levels. Atheroscler. Suppl. 2015; 18: 163–9. DOI: 10.1016/j.atherosclerosissup.2015.02.025
  26. Frischmann M.E., Kronenberg F., Trenkwalder E., Schaefer J.R., Schweer H., Dieplinger B. et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney. Int. 2007; 71: 1036–43. DOI: 10.1038/sj.ki.5002131
  27. Dentali F., Gessi V., Marcucci R., Gianni M., Grandi A.M., Franchini M. Lipoprotein(a) as a risk factor for venous thromboembolism: a systematic review and meta-analysis of the literature. Semin. Thromb. Hemost. 2017; 43 (6): 614–20. DOI: 10.1055/s-0036-1598002
  28. Bulaeva N.I., Goluhova E.Z. Endothelial dysfunc-tion and oxidant stress: the role in cardiovascularpathology. Creative Cardiology.2013; 1: 14–22(in Russ.).
  29. Nordestgaard B.G., Chapman M.J., Ray K., Boren J., Andreotti F., Watts G.F. et al. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart. J. 2010; 31: 2844–53. DOI: 10.1093/eurheartj/ehq386
  30. Emerging Risk Factors Collaboration, Erqou S., Kaptoge S., Perry P.L., Di Angelantonio E., Thompson A. et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and nonvascular mortality. JAMA. 2009; 302: 412–23. DOI: 10.1001/jama.2009.1063
  31. Emerging Risk Factors Collaboration, Di Angelantonio E., Gao P., Pennells L., Kaptoge S., Caslake M. et al. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012; 307: 2499–506. DOI: 10.1001/jama.2012.6571
  32. Bennet A., Di Angelantonio E., Erqou S., Eiriksdottir G., Sigurdsson G., Woodward M. et al. Lipoprotein(a) levels and risk of future coronary heart disease: large scale prospective data. Arch. Intern. Med. 2008; 168: 598–608. DOI: 10.1001/archinte.168.6.598
  33. O'Donoghue M.L., Morrow D.A., Tsimikas S., Sloan S., Ren A.F., Hoffman E.B. et al. Lipo-protein( a) for risk assessment in patients with established coronary artery disease. J. Am. Coll. Cardiol. 2014; 63: 520–7. DOI: 10.1016/j.jacc.2013.09.042
  34. Cai A., Li L., Zhang Y., Mo Y., Mai W., Zhou Y. Lipoprotein(a): a promising marker for residual cardiovascular risk assessment. Disease. Markers. 2013; 35 (5): 551–9. DOI: 10.1155/2013/563717
  35. Rifai N., Ma J., Sacks F.M., Ridker P.M., Hernandez W.J., Stampfer M.J., Marcovina S.M. Apolipoprotein( a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the physicians' health study. Clin. Chem. 2004; 50: 1364–71. DOI: 10.1373/clinchem.2003.030031
  36. Danik J.S., Rifai N., Buring J.E., Ridker P.M. Lipoprotein(a), measured with an assay independent of apolipoprotein (a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA. 2006; 296: 1363–70. DOI: 10.1001/jama.296.11.1363
  37. Khotsanyan Ch.V., Golukhova E.Z. Erectile dys-function as an early predictor of ischemic heartdisease. Creative Cardiology.2016; 10 (1): 37–53(in Russ.).
  38. Anderson T.J., Gregoire J., Hegele R.A., Couture P., Mancini G.B., McPherson R. et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can. J. Cardiol. 2013; 29: 151–67. DOI: 10.1016/j.cjca.2012.11.032
  39. Moriarty P.M., Minchew H.M., Oktona D.C. Treating lipoprotein(a)-hyperproteinemia and progressive cardiovascular disease with lipid-apheresis in North America. JACC. 2018; 71 (11): 1784. DOI: 10.1016/S0735-1097(18)32325-8
  40. Cioni G., Marcucci R., Abbate R., D'Alessandri G. Recurrent cardiac events driven by prothrombotic burden in a patient undergoing lipoprotein apheresis for high Lp(a) levels. Ann. Clin. Endocrinol. Metabol. 2017; 1: 001–5. DOI: 10.29328/journal.hcem.1001001
  41. Schmitz G., Orso E. Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects. Clin. Res. Cardiol. Suppl. 2015 (Suppl.) 10: 21–5. DOI: 10.1007/s11789-015-0074-0
  42. Ezhov M.V., Afanasieva O.I., Il'ina L.N., Safarova M.S., Pokrovsky S.N. Association of lipoprotein( a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis. Atheroscler. Suppl. 2017; 30: 187–92. DOI: 10.1016/j.atherosclerosissup.2017.05.011
  43. Kamstrup P.R., Tybjaerg-Hansen A., Nordestgaard B.G. Lipoprotein (a) and risk of aortic valve stenosis in the general population. Eur. Heart. J. 2013; 34: 1814. DOI: 10.1093/eurheartj/eht308.1814
  44. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z., Catapano A.L., De Backer G., Graham I., Taskinen M.R., Wiklund O. et al. ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart. J. 2011; 32: 1769–818. DOI: 10.1093/eurheartj/ehr158
  45. Piepoli M.F., Hoes A.W., Agewall S., Albus C., Brotons C., Catapano A.L. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Reha-bilitation (EACPR). Eur. J. Prevent. Cardiol. 2016; 23 (11): NP1–96. DOI: 10.1177/2047487316653709
  46. Jayasinghe R., Craig I.H., Mohan R.K.A. Lipoprotein (a) in clinical practice. J. Pak. Med. Assoc. 2014; 64 (4): 447–50.
  47. Abramyan M.V. Possibilities of LDL-apheresisin complex treatment of atherosclerosis. CreativeCardiology. 2007; 1–2: 208–19 (in Russ.).
  48. Thompson G.R., HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008; 198 (2): 247–55. DOI: 10.1016/j.atherosclerosis.2008.02.009
  49. Schettler V.J., Neumann C.L., Peter C., Zimmermann Th., Julius U., Roeseler E., Heigl F. et al. The German Apheresis Working Group. Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels. Clin. Res. Cardiol. Suppl. 2015; 10: 14–20. DOI: 10.1007/s11789-015-0073-1
  50. Pokrovsky S.N., Afanasieva O.I., Ezhov M.V. Lipoprotein( a) apheresis. Curr. Opin. Lipidol. 2016; 27 (4): 351–8. DOI: 10.1097/MOL.0000000000000319

About Authors

  • Mikhail B. Yaroustovsky, Professor, Corresponding Member of Russian Academy of Sciences, Deputy Director, Head of Department, ORCID;
  • Marina V. Abramyan, Cand. Med. Sc., Leading Researcher, ORCID

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


Sort by